Mice were randomly divided into six groups (n=6 mice/group) as follows: Control group, ovalbumin (OVA) group, GW3965 group, LXRα-/- group, LXRβ-/- group and LXRα/β knockout (KO) group. Certainwild-type mice received intervention with the LXR agonist GW3965 (Cayman Chemical Company) at 20 mg/kg by intraperitoneal injection. LXR-KOmice and wild-type mice were used to establish a chronic asthma model (18 (link)). Mice were intraperitoneally injected with 0.1 ml sensitizing solution [0.1 mg OVA; 0.07 ml Imject™ Alum Adjuvant (Beijing Biolead Biotechnology Co., Ltd.); 0.03 ml PBS] on days 0, 7 and 14. The mice were stimulated with 1% OVA solution using an ultrasonicnebulizer (402AI; Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.) from day 21 for 30 min each time, three times a week, for 8 consecutive weeks. Mice treated with the LXR agonist were administered an intraperitoneal injection of GW3965 at 20 mg/kg (10 (link),22 (link)) prior to each stimulation.